4//SEC Filing
Hefti Franz 4
Accession 0001209191-21-005438
CIK 0001714798other
Filed
Jan 25, 7:00 PM ET
Accepted
Jan 26, 5:15 PM ET
Size
10.6 KB
Accession
0001209191-21-005438
Insider Transaction Report
Form 4
Hefti Franz
Chief Development Officer
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−59,844→ 0 totalExercise: $10.26→ Common Stock (59,844 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−266,895→ 0 totalExercise: $0.18→ Common Stock (266,895 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-01-22−62,200→ 0 totalExercise: $16.91→ Common Stock (62,200 underlying)
Footnotes (1)
- [F1]Pursuant to the terms of the Merger Agreement, and as of immediately prior to the Effective Time, each of these options, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (A) an amount of cash (less applicable tax withholdings) equal to the product of (i) the excess, if any, of $22.50 per share of common stock underlying such stock option, net in cash, without interest, over the applicable exercise price per share underlying such stock option multiplied by (ii) the total number of shares subject to such stock option, and (B) one contingent value right per share for each share subject to such stock option immediately prior to the Effective Time (without regard to vesting).
Documents
Issuer
Prevail Therapeutics Inc.
CIK 0001714798
Entity typeother
Related Parties
1- filerCIK 0001735529
Filing Metadata
- Form type
- 4
- Filed
- Jan 25, 7:00 PM ET
- Accepted
- Jan 26, 5:15 PM ET
- Size
- 10.6 KB